JP2023549854A - 肝臓特異的Wntシグナル増強分子およびその使用 - Google Patents
肝臓特異的Wntシグナル増強分子およびその使用 Download PDFInfo
- Publication number
- JP2023549854A JP2023549854A JP2023528657A JP2023528657A JP2023549854A JP 2023549854 A JP2023549854 A JP 2023549854A JP 2023528657 A JP2023528657 A JP 2023528657A JP 2023528657 A JP2023528657 A JP 2023528657A JP 2023549854 A JP2023549854 A JP 2023549854A
- Authority
- JP
- Japan
- Prior art keywords
- liver
- seq
- molecule
- certain embodiments
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114457P | 2020-11-16 | 2020-11-16 | |
| US63/114,457 | 2020-11-16 | ||
| US202163182106P | 2021-04-30 | 2021-04-30 | |
| US63/182,106 | 2021-04-30 | ||
| US202163248157P | 2021-09-24 | 2021-09-24 | |
| US63/248,157 | 2021-09-24 | ||
| PCT/US2021/059564 WO2022104280A1 (en) | 2020-11-16 | 2021-11-16 | Liver-specific wnt signal enhancing molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549854A true JP2023549854A (ja) | 2023-11-29 |
| JP2023549854A5 JP2023549854A5 (cg-RX-API-DMAC7.html) | 2024-11-15 |
Family
ID=81602651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528657A Pending JP2023549854A (ja) | 2020-11-16 | 2021-11-16 | 肝臓特異的Wntシグナル増強分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12240876B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4243878A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023549854A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230109668A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021379770A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198268A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202233656A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022104280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018211985B2 (en) | 2017-01-26 | 2025-02-13 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses thereof |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング, インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン, インコーポレイテッド | 組織特異性Wntシグナル増強分子及びその使用 |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020014271A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses |
| JP2020506701A (ja) * | 2017-01-26 | 2020-03-05 | スロゼン, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE60129799T2 (de) | 2000-03-31 | 2008-04-30 | The General Hospital Corp., Boston | Verfahren zur steigerung des haarwuchses durch wnt polypeptid |
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ATE466106T1 (de) | 2003-10-10 | 2010-05-15 | Deutsches Krebsforsch | Zusammensetzungen für die diagnose und therapie von erkrankungen, die im zusammenhang mit einer anomalen expression von futrinen (r-spondinen) stehen |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US8221751B2 (en) | 2006-06-21 | 2012-07-17 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof |
| EP2548576B1 (en) | 2006-08-14 | 2016-11-30 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis of cancer using anti-desmoglein-3 antibodies |
| ES2610474T3 (es) | 2007-01-11 | 2017-04-27 | Michael Bacher | Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia |
| WO2008093646A1 (ja) | 2007-02-01 | 2008-08-07 | National University Corporation NARA Institute of Science and Technology | Wntシグナル伝達系活性化ペプチド |
| EP2331136B1 (en) | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| US8642339B2 (en) | 2009-02-03 | 2014-02-04 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| WO2010092457A1 (en) | 2009-02-10 | 2010-08-19 | Nokia Corporation | Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment |
| EP2305274A1 (en) | 2009-09-21 | 2011-04-06 | Centre National de la Recherche Scientifique (CNRS) | Use of WNT stimulators for treating demyelinating diseases |
| MX2012006593A (es) | 2009-12-09 | 2012-06-28 | Bayer Pharma AG | Anticuerpos anti-c4.4a y usos de los mismos. |
| CN102971337B (zh) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| WO2011130624A2 (en) | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| US10086043B2 (en) | 2011-04-03 | 2018-10-02 | The General Hospital Corporation | Efficient protein expression in vivo using modified RNA (MOD-RNA) |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2769786T3 (es) | 2011-10-14 | 2020-06-29 | Recordati Ag | Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt |
| WO2013071047A1 (en) | 2011-11-11 | 2013-05-16 | Children's Medical Center Corporation | Compositions and methods for in vitro transcription of rna |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| BR112014020233A2 (pt) | 2012-02-28 | 2017-07-04 | Irm Llc | seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43 |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2014023709A1 (en) | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| BR112016024525A2 (pt) | 2014-04-21 | 2017-10-10 | Abbvie Stemcentrx Llc | novos anticorpos anti-rnf43 e métodos de uso |
| JP6796059B2 (ja) | 2014-09-12 | 2020-12-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Wntシグナリングアゴニスト分子 |
| AU2015340056A1 (en) | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| SG11201708491PA (en) | 2015-04-17 | 2017-11-29 | Merrimack Pharmaceuticals Inc | Combination treatments with seribantumab |
| JP7296728B2 (ja) | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| MY207684A (en) | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| US20170349659A1 (en) | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| AU2017363309A1 (en) | 2016-11-23 | 2019-07-11 | Bioverativ Therapeutics Inc. | Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X |
| WO2018107116A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| JP7617603B2 (ja) | 2017-01-11 | 2025-01-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | R-スポンジン(rspo)サロゲート分子 |
| US20200123256A1 (en) | 2017-05-02 | 2020-04-23 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| GB201708330D0 (en) | 2017-05-24 | 2017-07-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Fusion protein for enhancing intestinal regeneration |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング, インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| AU2019297522B2 (en) | 2018-07-05 | 2026-04-23 | Surrozen Operating, Inc. | Multi-specific Wnt surrogate molecules and uses thereof |
| US20220064337A1 (en) | 2018-12-19 | 2022-03-03 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| AU2020221797A1 (en) | 2019-02-11 | 2021-08-12 | Surrozen Operating, Inc. | Modulation of WNT signalling in ocular disorders |
| WO2020185960A1 (en) | 2019-03-11 | 2020-09-17 | Surrozen, Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| US20220175884A1 (en) | 2019-04-02 | 2022-06-09 | Surrozen Operating, Inc. | Modulation of wnt signaling in auditory disorders |
| KR20220024460A (ko) | 2019-06-11 | 2022-03-03 | 안틀라 테라퓨틱스 아이엔씨. | 다가 fzd 및 wnt 결합 분자 및 이의 용도 |
| US11050604B2 (en) | 2019-07-01 | 2021-06-29 | Rampart Communications, Inc. | Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation |
| US20230138045A1 (en) | 2020-02-24 | 2023-05-04 | Surrozen Operating, Inc. | Wnt super agonists |
| WO2022104280A1 (en) | 2020-11-16 | 2022-05-19 | Surrozen Operating, Inc. | Liver-specific wnt signal enhancing molecules and uses thereof |
| JP7891006B2 (ja) | 2021-03-10 | 2026-07-15 | スロゼン オペレーティング, インコーポレイテッド | 胃腸障害におけるwntシグナル伝達のモジュレーション |
| EP4401841A4 (en) | 2021-09-14 | 2025-07-02 | Surrozen Operating Inc | MODULATION OF WNT SIGNALING IN PULMONARY DISORDERS |
| CA3240866A1 (en) | 2021-12-17 | 2023-06-22 | Surrozen Operating, Inc. | Wnt-surrogate agents and methods for lacrimal gland regeneration |
-
2021
- 2021-11-16 WO PCT/US2021/059564 patent/WO2022104280A1/en not_active Ceased
- 2021-11-16 JP JP2023528657A patent/JP2023549854A/ja active Pending
- 2021-11-16 CA CA3198268A patent/CA3198268A1/en active Pending
- 2021-11-16 EP EP21893034.5A patent/EP4243878A4/en active Pending
- 2021-11-16 KR KR1020237019853A patent/KR20230109668A/ko active Pending
- 2021-11-16 TW TW110142656A patent/TW202233656A/zh unknown
- 2021-11-16 AU AU2021379770A patent/AU2021379770A1/en active Pending
-
2023
- 2023-05-02 US US18/311,082 patent/US12240876B2/en active Active
-
2025
- 2025-01-28 US US19/039,360 patent/US20250171509A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020506701A (ja) * | 2017-01-26 | 2020-03-05 | スロゼン, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
| WO2020014271A1 (en) * | 2018-07-09 | 2020-01-16 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses |
| JP2021530223A (ja) * | 2018-07-09 | 2021-11-11 | スロゼン, インコーポレイテッド | 組織特異性Wntシグナル増強分子及びその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202233656A (zh) | 2022-09-01 |
| EP4243878A1 (en) | 2023-09-20 |
| CA3198268A1 (en) | 2022-05-19 |
| AU2021379770A9 (en) | 2024-06-06 |
| KR20230109668A (ko) | 2023-07-20 |
| WO2022104280A1 (en) | 2022-05-19 |
| AU2021379770A1 (en) | 2023-06-22 |
| US20230374090A1 (en) | 2023-11-23 |
| EP4243878A4 (en) | 2025-05-14 |
| US20250171509A1 (en) | 2025-05-29 |
| US12240876B2 (en) | 2025-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240279303A1 (en) | Tissue-specific wnt signal enhancing molecules and uses thereof | |
| US12466884B2 (en) | Tissue-specific WNT signal enhancing molecules and uses | |
| US12240876B2 (en) | Liver-specific Wnt signal enhancing molecules and uses thereof | |
| US20250313616A1 (en) | Modulation of wnt signalling in ocular disorders | |
| AU2018393073A1 (en) | Wnt surrogate molecules and uses thereof | |
| CN112566940A (zh) | 多特异性wnt替代分子和其用途 | |
| JP2021508247A (ja) | 抗フリズルド抗体及び使用方法 | |
| CN121568704A (zh) | 用于泪腺再生的wnt替代剂和方法 | |
| WO2016135462A1 (en) | Treatment | |
| CN116723867A (zh) | 肝脏特异性Wnt信号增强分子及其用途 | |
| JP5971966B2 (ja) | Tdp−43の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬 | |
| TW202146429A (zh) | C4結合蛋白之c端片段與血管生成素-1之類纖維蛋白原結構域之間之嵌合融合作為治療血管疾病之血管生成素模擬物及tie2促效劑 | |
| TW202200606A (zh) | C4結合蛋白之C端片段與血管生成素-1之類纖維蛋白原結構域之間之嵌合融合作為治療血管疾病之血管生成素模擬物及Tie2促效劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260519 |